Sangamo Therapeutics' fair value has been revised downward, primarily reflecting meaningful declines in both its forward P/E multiple and net profit margin, resulting in a lower consensus price target of $2.62.
What's in the News
- Sangamo presented detailed data from the registrational Phase 1/2 STAAR study of isaralgagene civaparvovec (ST-920), its investigational gene therapy for adults with Fabry disease, showing a positive mean annualized eGFR slope of 1.965 mL/min/1.73m2/year in all patients followed at least 12 months.
- Updated results indicate that for the first 19 patients with 104-week follow-up, the observed positive mean annualized eGFR slope compares favorably to current Fabry disease treatments, which show negative or less favorable slopes.
- Isaralgagene civaparvovec has received Orphan Drug, Fast Track, and RMAT designations from the FDA, Orphan Medicinal Product designation and PRIME eligibility from the EMA, and Innovative Licensing and Access Pathway from the UK MHRA.
- Sangamo faces significant capital constraints and risks to its ability to continue operations, requiring substantial additional funding or partnerships, especially to advance the Fabry disease program.
- The company intends to conduct further comparative analyses against existing therapies and is planning to present additional data at upcoming medical meetings.
Valuation Changes
Summary of Valuation Changes for Sangamo Therapeutics
- The Consensus Analyst Price Target has significantly fallen from $4.10 to $2.62.
- The Future P/E for Sangamo Therapeutics has significantly fallen from 68.47x to 49.77x.
- The Net Profit Margin for Sangamo Therapeutics has significantly fallen from 16.06% to 14.17%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.